



EUROPEAN LUNG FOUNDATION





It is a privilege to connect with you once again as we reflect on another remarkable year at the European Lung Foundation (ELF). Over the past months, I have seen our community grow stronger and even more committed to improving the lives of people with lung conditions.

This year, our work has taken on a broader perspective, focusing on global challenges. Through collaboration with the World Health Organization (WHO), we are tackling issues that affect patients everywhere, recognising that lung health is shaped not only by biology but also by our environment. A highlight for me was my invitation to speak at the <a href="https://www.who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wight.com/who.en.wigh

Patient advocacy is central to ELF and has been a major part of my journey with the organisation since receiving the ELF Award in 2021. It has been exciting to see our advocacy work being strengthened by the work of the Lungs Europe team, who were awarded an operating grant to deliver this vital work this year. Thanks to Lungs Europe, patients participated in key events including the Healthy Lungs for Life (HLfL) exhibition in the European Parliament and more regionally-focused events to support the respiratory community in Ukraine. These examples show how vibrant our network is and how ELF can play a role in turning patient engagement into real change.

Our partnership with ERS continues to strengthen and the 2025 strategy update earlier this year gave it fresh momentum. By formally recognising the importance of patient involvement, the update reinforces ELF's role in shaping projects and policy initiatives, ensuring patient priorities reach every level of the respiratory community.

At the heart of ELF are the people who make it happen. Patients, professionals, volunteers, and advocates bring unique skills and perspectives, and by working side by side, we co-create solutions that empower communities and drive real change. In this report, I am delighted to share our progress and celebrate the impact of our collective efforts.

Every breath matters. Together, we are making each one count.

ELF STRATEGY 2023-2026

BE PATIENT DRIVEN

ELF will ensure that patients and patient organisations drive its activities and that they are at the heart of all that it does.

Page 4

IMPROVE KNOWLEDGE AND UNDERSTANDING

ELF will further develop its health and science communication and provide accurate and evidence-based information for patients and the public in new formats.

Page 9

ENGAGE AND EMPOWER

engagement and involvement to improve diagnostics, treatment and care in all lung conditions and promote selfmanagement.

<u>Page 11</u>

HAVE A STRONG AND DIVERSE COMMUNITY AND VOICE

ELF will participate in and help build advocacy projects to advance the lung health agenda.

<u>Page 13</u>

ENSURE GOOD GOVERNANCE

To deliver on the ELF strategy, the governance of ELF must be effective and efficient for employees and collaborators.

<u>Page 17</u>

INCREASE RESOURCE AND REACH

ELF must continue to diversify its income to ensure it can deliver on its aim to reach more people.

<u>Page 18</u>

You can read a full overview of the ELF Strategy Report on our website.



At the European Lung Foundation, we believe that people living with lung conditions should help shape the research, care and information that affects them. This year, we continued to make sure that patient voices are included in all areas of our work.

"Hearing directly from patients brings their experiences to life and reminds us that our involvement with ELF really matters. Every opportunity for a patient to share their story, whether through a video, an online conference or an international event, is a chance to learn from each other and improve health outcomes for everyone. It is wonderful to see that the platforms for patients to share their experiences are continuing to grow at ELF."



Helen Parks, ELF Council and United Patient Advisory Group (UPAG) Chair

15

patient advisory groups

5

cross-disease working groups

3

EU project-specific patient groups

76

patient participation opportunities in events

The ELF patient advisory groups and working groups are made up of people who have an interest in a particular lung condition or topic related to lung health. Volunteers share their views and experiences and get involved in projects to help improve treatment and healthcare. This shapes our activities throughout the year, including patient conferences, updates to educational resources, contributions to professional guidelines for healthcare professionals and collaborations with respiratory partners and organisations. Alongside these groups, the United Patient Advisory Group (UPAG), the Patient Advisory Committee (PAC) and the ELF Council complete the ELF structure. These groups play a key role in shaping, overseeing and ensuring the successful delivery of ELF's strategy.



Sharing real stories

We produced 24 new "<u>Your Experience</u>" videos, where patients spoke about living with lung conditions. These short films were shared on our website and social media channels.

Popular topics included:

- <u>Lung transplantation: personal experiences</u>
- Air pollution and living with severe asthma
- A patient's journey taking part in a clinical trial
- <u>Pulmonary Arterial Hypertension: a patient's</u> <u>journey</u>

Increased visibility and opportunities for patient activities

This year, we launched new <u>patient advisory group</u> (<u>PAG) webpages</u> to showcase each group's members, priorities and ongoing activities.

These pages provide greater visibility for patient involvement across ELF's work and offer a platform to highlight the valuable contributions of our patient representatives and volunteers. By making this information more accessible, we aim to strengthen collaboration, raise the numbers in our community and increase opportunities for patients to get involved in shaping lung health initiatives.

These highlights represent just a selection of this year's activities from our PAGs:

- The Aspergillosis PAG restarted in November 2024, helping people with this rare lung condition share experiences and advice.
- The Pulmonary Hypertension PAG hosted a live Q&A session in May 2024, where patients could ask questions directly to experts.
- The Pulmonary Fibrosis PAG worked with researchers on a survey about access to oxygen therapy across Europe. The results will help support future campaigns.
- The Bronchiectasis PAG contributed to new ERS guidelines on managing adult bronchiectasis.
 They also presented and led discussions at the 7th World Bronchiectasis Conference in Dundee and the European Bronchiectasis Workshop in Paris.
- The Sleep PAG prepared for 2 conferences this year: the ERS Sleep and Breathing Conference for healthcare professionals and ELF's Living with Sleep and Breathing Disorders event aimed at patients. They conducted a survey on diagnosis and treatment experiences, with results due to be shared during the conferences in April 2025.



Working together to develop patient conferences:

ELF patient conferences are free online events that connect people with lung conditions, their families, healthcare professionals and researchers to share upto-date information on a lung condition or related topic. Each conference features expert talks, patient experiences and Q&A sessions to help attendees understand and manage their condition.

Chronic Cough patient conference (October 2024)

• 108 people attended on the day and the recordings have been viewed over 1,000 times.

<u>Alpha-1 Antitrypsin Deficiency patient conference</u> (November 2024)

 212 people attended from 35 countries; the conference was developed in collaboration with the European Alpha-1 Research Collaboration (EARCO), the European Reference Network ERN-Lung and the Alpha-1 Europe Alliance.

Breathe Clean Air patient conference (January 2025)

• 91 people attended, with positive feedback on the speakers and programme.

Bronchiectasis patient conference (March 2025)

 529 people attended from 63 countries, with 380 questions asked and answered during the sessions.

Other events and webinars:

- Pulmonary Hypertension Question Time
- Childhood Bronchiectasis Question Time
- Mental Health and Lung Conditions: action and awareness (Feb 2025)
- World Bronchiectasis Day Question Time (July 2024)

"I loved hearing about the positive future for us all. I came away feeling uplifted and happy, looking forward to my life with my little ones rather than worrying about how it will be.

Also, being able to ask questions to those leading the field was a truly amazing experience and I felt honoured to have my questions answered by such important people who have a wealth of knowledge to share with us patients. I really felt we were all helping and supporting each other."

Bronchiectasis Patient Conference attendee, 2025





52 projects in collaboration with ERS

including 31 task forces and 21 Clinical Research Collaborations (CRCs).

Patient involvement in ERS activities and publications accelerates each year with a range of publications, lay guidelines and patient-facing materials produced as a result.

The ERS 'Guidelines in Focus' video interview series, launched in 2023, continued this year and featured patient perspectives alongside new clinical guidelines and standards.

- ERS Clinical Practice Guideline on symptom management for adults with serious respiratory illness
- ERS Clinical Practice Guideline on telemedicine in home mechanical ventilation

- ELF patient representatives worked with the <u>AMR-Lung CRC</u> to develop a survey on "Antibiotics and Antimicrobial Resistance (AMR) in Chronic Lung Disease: Patient Perspectives." The survey explores patient experiences and understanding of AMR, with results due in summer 2025.
- In October 2024, ELF hosted a <u>Childhood Bronchiectasis</u>
 <u>Question Time webinar</u> in collaboration with the <u>ChildBEARNet CRC</u>. The session addressed 25 patient-submitted questions and attracted attendees from 13 countries, showing the global relevance of the topic.
- The <u>EMBARC CRC</u> continues to work closely with the <u>ELF</u>
 <u>Bronchiectasis PAG</u> to integrate patient perspectives into
 bronchiectasis research and clinical practice. This year,
 patients contributed to the design and delivery of the GREAT-2
 and AIRNET clinical trials, led by EMBARC with LifeArc.
 EMBARC also partnered with patients to deliver the annual
 <u>Bronchiectasis Patient Conference</u>, now in its 5th year.
- Members of the <u>ELF Asthma PAG</u> continue to play an active role in the <u>SHARP CRC</u>, helping to ensure specialised care for people with severe asthma across Europe. Hilary Hodge, SHARP's patient chair, recently met with national leads to emphasise the importance of patient involvement and to keep patient priorities at the heart of SHARP's work.













My life has never been an easy one. By the age of seven, I already knew I had a rare, incurable disease that I would have to live with. Despite this, I threw myself into life—balancing fun, studies, and work—to make the most of every moment.

Work, however, was my first major disappointment. Being excluded because of the progression of my illness was a painful blow. But it also gave me the strength to refocus on my future. I began the long journey toward a lung transplant—an immense challenge, but one that ultimately gave me back a real, full life.

Everything went so well that I soon decided to dedicate my time to helping others going through similar experiences. That opportunity came when I was asked to take over a small lung transplant association founded a few years earlier by patients from our centre. We started with just 35 members, but I quickly saw the need to connect and collaborate with other organisations.

That's how we found a welcoming home in ELF. No one judged us for our lack of experience or small size. We were embraced with open arms. I owe much of my growth as a representative of transplant patients and those with rare lung diseases to ELF. Year after year, I was entrusted with increasingly meaningful responsibilities, which helped me move beyond the disappointments I had experienced in the professional world.

As I grew, so did our association. Today, it plays an important role in Italy, supporting patients at all stages of transplantation and those living with interstitial lung diseases.

I have been a member of the Patient Advisory Committee (PAC) for some time now. Over the past year, along with other dedicated colleagues, I have helped establish the Transplantation Working Group. With the continued support of ELF and the ELF Chair, Dimitris, I am confident this group will become a key point of reference across Europe for the lung transplant community—a community still facing many unmet needs and serious issues of exclusion, particularly in Eastern Europe.

Knowing that there are still people who cannot access the chance at a second life, often for political reasons, is heartbreaking and infuriating. And those who know me, know how passionate my Italian spirit can be. I hope to continue this journey alongside ELF for many years to come, because I truly believe that ELF is the European home for all people living with lung diseases.

ELF helps people understand their condition and improve their lung health by creating easy-to-read, trustworthy information. We work with experts and patients to ensure our content is accurate, up to date and available in many languages. Beyond information, ELF supports capacity building and effective communication through a range of initiatives. We offer lay communication training to help patient representatives and partners communicate complex lung health topics clearly and confidently. We have delivered tailored training to EU projects such as OPTIMA and to ERS early career professionals through our fellowship training programmes.

19

new and reviewed information pages

This year, updates across the comprehensive ELF information hub became a priority. Nine existing pages received major edits this year and a further 10 pages were reviewed and either republished or taken offline. Key updates included:

- Chronic cough
- <u>Sleep disordered</u> breathing
- <u>Lung transplant</u>, including a patient perspective booklet.

3

lay guidelines and resources

18

Lay research summaries

17

ELF contributions to publications



This year, our European Patient Ambassador Programme (EPAP) Live sessions have continued to provide a dynamic platform for patients to engage directly with experts and advocate for better lung health. These interactive webinars complement our free, online, self-learning programme, which equips patient representatives with the skills and knowledge to effectively share their views and experiences.

Our sessions have covered key topics including:

- <u>EU Projects</u> exploring opportunities for patient involvement in EU-funded initiatives
- <u>EU Advocacy</u> strategies for influencing health policy at the European level
- Healthy Lungs for Life Grants understanding their impact and how patients can benefit.


Through lively discussions, practical exercises, and expert insights, participants have strengthened their confidence and capability to take an active role in shaping respiratory healthcare. By fostering collaboration across countries, organisations, and patient communities, EPAP Live has created a truly inclusive learning environment. Looking ahead, we are committed to expanding these opportunities, ensuring that patient voices continue to drive meaningful change in lung health policy and practice across Europe.

EPAP is a free, online, self-learning programme that introduces patients and carers to some of the basic skills and knowledge needed to represent themselves and others successfully. Training modules include:

- Being better informed
- Improving awareness
- Improving treatment and care
- Supporting research and development

- Influencing policy
- Working with the media
- Participating in healthcare conferences
- International health research projects.

3. ENGAGE AND EMPOWER



ELF continues to explore innovative ways to engage diverse audiences worldwide. Our digital platforms remain central to this mission, enabling us to lead in patient involvement and engagement by:

- Expanding recruitment for our patient communities and active participation in EU projects
- Delivering accurate, evidence-based information on lung health, prevention, and advocacy
- Highlighting news and updates from organisations across the ELF patient network
- Fostering meaningful dialogue and connection among patients, healthcare professionals, and the public on key lung health topics.

873
thousand
website users

million webpage views

thousand newsletter subscribers

28.3 thousand social media followers

Supported by content from our patient advisory groups and partners, ELF has further accelerated its social media presence this year. We increased visual content and nearly doubled the number of posts across platforms, helping us engage new audiences and connect more effectively with those benefiting from resources in our information hub.



8,391 FOLLOWERS
Post engagement N/A




13,886 FOLLOWERS
Post engagement 3.23%



2,990 FOLLOWERS
Post engagement 7.09%



3,068 FOLLOWERS
Post engagement 9.02%



This year, our mailing strategy evolved with the continued split into two monthly updates: the ELF Newsletter and the Patient Voice mailing. The Patient Voice newsletter highlights our patient-centred content and opportunities and includes the monthly Patient Organisation Round-up, increasing visibility for topics that matter most to our patient organisation network.

We increased the frequency of direct single-message mailings about events and opportunities for subscribers who opted in. This shift is reflected in the significant jump in the total number of mailers sent, helping to boost engagement and provide more tailored, relevant information.

Audience summary:



	MARCH 2024	MARCH 2025
ELF Newsletter	11,520	11,875
Patient Voice mailing	11,387	11,495

Email performance:



	2023/2024	2024/2025
Emails sent	172,754	301,817
Average open rate	36.4%	41.2%
Average click rate	3.2%	3.4%

Subscribe to ELF mailings here: www.europeanlung.org/en/news/newsletters

4. HAVE A STRONG AND DIVERSE COMMUNITY AND VOICE



ELF continues to participate in and support advocacy initiatives that advance lung health across Europe. Through these activities, we work closely with patients to amplify their voices and experiences—for example, through patient speakers at the ERS Congress, participation in EU projects, and engagement in events in Brussels.

In partnership with ERS, we bring patients and the public together with healthcare professionals to improve lung health and advance diagnosis, treatment, and care. Our work in advocacy is further strengthened through initiatives such as Lungs Europe, the MEP Lung Health Group, and the European Lung Health Group. A more detailed overview of these activities and their impact can be found <u>in the Lungs Europe 2024/25</u>

Annual Report.



Feedback from patients and professionals at the ERS Congress:

"A patient video brings a personal, emotional dimension to the scientific discussion. It allows participants to connect with the lived experience of the patient, which can sometimes get lost in purely clinical presentations."

"When a patient's journey is presented, it opens up discussions on ethical concerns, such as quality of care, access to treatment, and the ethical considerations in clinical decision-making. This can enrich the round table conversation by integrating ethical dimensions into scientific research and practice."

"Patient involvement brings very new and important aspects into symposia and is an outstanding contribution for everyone. Thanks to ELF for making this possible."

"Thank you for the opportunity to share my lived experience as part of ERS. The video turned out so well and I have had some lovely feedback from people in attendance."





7-11 September | Vienna, Austria

Patients at ERS Congress, Vienna 2024

The European Respiratory Society (ERS) Congress 2024 took place from 7–11 September as a hybrid event, with the option to join online or attend in person in Vienna, Austria. ELF remains committed to ensuring that patients, patient representatives and patient organisations have meaningful opportunities to take part in the Congress and share their valuable insights and experiences. **The 2024 Congress theme, 'Humans and machines: getting the balance right',** offered a timely opportunity to reflect on the role of technology in respiratory healthcare and the importance of keeping patients at the centre of care.

17 patients took part in 15 videos

Participants were from UK (9), Netherlands (1), Poland (1), Germany (1), Greece (1), Australia (1), Norway, Malaysia and Italy. 2 patients recorded in a language other than English

142

registrations

from organisations and patient representatives

ELF Patient Organisation Networking Day

The ELF Patient Organisation Networking Day is an annual event held during the ERS Congress that brings together members of the ELF Patient Organisation Network to explore key topics in lung health. The 2024 event focused on driving policy and healthcare change. It featured a keynote speech from Dr Maria Neira (WHO) and interactive sessions on air pollution, access to care, digital health, and more. It was delivered in a hybrid format, offering participants the chance to attend in person in Vienna or join online.

89

attended in Vienna

29

countries represented

85%

rated the event as good or excellent





Our active participation in EU projects and international committees is essential to placing patients' voices at the forefront of progress. As partners, leads, and contributors in these initiatives, we ensure that patients remain central to cutting-edge research and policy development. Examples of projects we support this year are:

3TR

The 3TR respiratory patient group met regularly throughout the year to provide feedback and guidance on the 3TR Asthma Biologic Cohort (ABC) study. In June 2024, members attended the 3TR Annual Meeting in Sweden alongside the wider cross-disease patient group. They gave a presentation on patient involvement in the project to date and participated in a panel discussion on patient-reported outcome measures, which was co-chaired by ELF Director Pippa Powell. More recently, the cross-disease patient panel was formally included in the governance of 3TR following consortium agreement that the patient voice should be officially recognised.



UNITE4TB

Members of the UNITE4TB Community Advisory Group (CAG) have continued to meet every 6 weeks with clinical trial and consortium representatives. They have reviewed protocols, patient and public involvement (PPI) plans and recruitment materials and supported engagement with trial site teams from the PARADIGM4TB trial to exchange best practice and explore ongoing challenges. In May 2024, four CAG members attended the **UNITE4TB Annual Meeting in Uppsala**. They participated in a joint symposium with ERA4TB on community engagement, gave a presentation on their activities to the wider consortium and took part in a focus group on engagement strategies.



OPTIMA

In May 2024, 3 members of the OPTIMA Public and Patient Advisory Board (PPAB) attended **the project's Annual General Meeting in Madrid** and gave a presentation on their activities. Over the year, PPAB members have continued to contribute actively to the project, providing feedback on the Clinical Decision Support Tool and taking part in discussions about access to the OPTIMA system. In early 2025, work package leads were consulted on how to involve the PPAB more effectively, and a detailed workplan was produced to guide activities for the rest of the year.





This year, we honoured physician and researcher, Dr Walter Klepetko, with the 2024 ELF Award. This was in recognition of his groundbreaking work in establishing an EU-wide lung transplant training programme that improves access to life-saving transplants across Europe. The award recognises individuals who have made an outstanding contribution to lung health and patient care.

Dr Klepetko leads the largest lung transplant centre in Europe at the Medical University of Vienna, where his team runs a twice-yearly lung transplant academy and offers extended scholarships for specialised training. Their efforts have strengthened international collaboration and helped establish independent transplant programmes in countries including the Czech Republic, Hungary, Estonia, Slovenia, Croatia, Greece and Ukraine. This has significantly expanded access to transplantation for patients in regions where it was previously unavailable.

"The chances of receiving a lung transplant vary greatly across Europe. In some countries, lung transplantation has not been an option for a long time," said Dr Klepetko.

Dimitris Kontopidis, ELF Chair, reflected on the life-saving impact of Dr Klepetko's work:

"Walter's commitment has created opportunities for lung transplantation regardless of nationality or residence, saving many lives. Supporting national programmes in countries with fewer resources embodies ELF's mission to advocate for equal access to healthcare without borders."

Dr Klepetko's work exemplifies ELF's ongoing dedication to widening access to critical treatments and improving the quality of life for people with chronic lung conditions.



ELF Chair's Campaign 2023-2026: a focus on transplantation

The Chair's Campaign, led by Dimitris Kontopidis, promotes equal access to lung transplantation in Europe. Running until 2026, it raises awareness, shares patient stories, engages communities and advocates for improvements in care to reduce inequalities. For details or to get involved, <u>visit the ELF website or contact the campaign team.</u>

5. ENSURE GOOD GOVERNANCE



To deliver on the ELF strategy, effective and efficient governance remains essential. Our governance structures bring together patients, experts and staff to guide and oversee ELF's work. This year, our councils and committees continued to meet regularly to ensure projects align with our strategic priorities.

In 2024/2025 we strengthened the ELF Core Council with the appointment of Natalia Maeva, President of the Bulgarian Society of Patients with Pulmonary Hypertension (BSPPH). Natalia's experience is helping to enhance the role of working groups and support collaboration across PAGs. Our **cross-condition working groups** continue to provide a platform for patients and experts to discuss shared challenges, enabling PAGs to work together on issues affecting all lung patients

Kjeld Hansen, former ELF Chair, continued his engagement with the WHO as a member of the WHO Civil Society Commission (WHO CSC). In 2024, he attended Thailand's 17th National Health Assembly as part of the WHO CSC steering committee, representing ELF. The assembly focused on the theme "New Wealth for Health," exploring how Universal Health Coverage (UHC) can be achieved to reduce healthcare inequalities and ensure that no one is left behind. Kjeld's continued participation emphasises the importance of empowering people with lived experience of disease to make their voices heard, strengthen trust in healthcare systems and contribute to better health outcomes.

We have also continued to increase the capacity and impact of our Youth Group and PAGs, providing more opportunities for patients to engage, lead and contribute to our work. We also maintain a strong feedback culture, requesting input from attendees and contributors after every event to ensure that our activities remain relevant, impactful and patient-focused.

6. INCREASE RESOURCE AND REACH



ELF recognises the critical need to diversify its income streams to ensure longterm sustainability. This approach will enable us to continue delivering on our strategic objectives while expanding our outreach to benefit a larger number of people and patients worldwide.

- This year, ELF's fundraising reached £139,222.29, a clear testament to the trust and support of our donors. We are excited to build on this momentum, expanding partnerships and enabling even greater impact for people living with lung conditions.
- By developing strategic partnerships, ELF maximises the impact of its funding through initiatives like Healthy Lungs for Life and the global community grants programme.
- We held our <u>Annual Stakeholder Meeting in October 2024</u> to review achievements from the past year and give stakeholders the chance to contribute to strategic priorities for the next financial year. The event also acknowledged the vital role of volunteers and supporters, inviting their input on future funding priorities and initiatives. During the meeting, we reflected on recent work and presented strategic priorities for 2025 and beyond, encouraging open discussion to ensure stakeholder voices shape our direction.

We gratefully acknowledge the organisations whose donations have supported Healthy Lungs for Life and ELF activities this year:














Healthy Lungs for Life, Vienna 2024

The <u>Healthy Lungs for Life (HLfL) campaign</u> took place in Vienna during the ERS Congress, where ELF shared findings from the LEAD project on air pollution's effect on adolescent lung health. The campaign included public lung testing, a 'Take the Active Option' walk/run open to Congress delegates and the Vienna public and school engagement. HLfL also featured in a prevention workshop for Congress delegates where ERS President Monika Gappa and Dr Breyer-Kohansal stressed the importance of raising awareness and driving policy change.

740+

people had their lungs tested during public events

500+

people joined the "Take the Active Option" event 190+

students educated on lung health during school visits

150+

delegates attended the ERS Congress workshop

Launch of the 10 year report

In 2024, the campaign celebrated 10 years of raising lung health awareness with the release of its **10-year report**. The report highlights achievements in advocacy, community initiatives and education programmes.




Healthy Lungs for Life community grants


Thanks to the support of the Forum of International Respiratory Societies (FIRS), <u>ELF</u> <u>awarded 10 grants</u> in 2024 to organisations promoting the HLfL campaign through local activities. The selected projects come from Bangladesh, Ghana, Uganda, Moldova, Tanzania, Guatemala, India, Uzbekistan, Nigeria and Ecuador. All community grant reports are <u>published on the ELF website</u> once submitted by the awardees.

Working together for clean air in Colombia

In March 2025, HLfL activities took place in Cartagena, Colombia, alongside the WHO Global Conference on Air Pollution and Health. In Parque Centenario, HLfL partnered with the World Heart Federation and local organisations to offer free lung and heart health checks, demonstrating how air pollution affects the body. WHO conference delegates observed the outreach, showcasing HLfL's adaptability in engaging communities and amplifying patient voices to raise global awareness of lung health.

FINANCIAL REVIEW 2024/25





SUPPORT OUR WORK

USE YOUR VOICE AND EXPERIENCE

Patient voices matter. We are always introducing more opportunities for patients to contribute to our work. Get involved in our disease-specific patient advisory groups (PAGs) or new cross-disease working groups.

If you want to use your experiences to help others, to inform healthcare professionals and to shape policy decisions then please consider joining Team ELF!

GET INVOLVED

VOLUNTEER YOUR TIME, SKILLS AND KNOWLEDGE

There are many ways to support our work, from helping to offer spirometry tests at ERS Congress and our Healthy Lungs for Life events, to translating our lay texts into multiple languages.

Volunteering your time and skills helps us to keep costs down and focus our resources on trying to engage new audiences, launch new campaigns and take part in more projects.

GET IN TOUCH

DONATE!

ELF continues to ensure patients are at the heart of our work.

Please help us to continue this work and become a regular donor today. Your donations help us to plan for our future and ensure that lung health patients continue to have their voices heard on a European and global level.

DONATE TODAY

EUROPEAN LUNG FOUNDATION



ELF is a patient-led organisation that works internationally to bring patients and the public together with healthcare professionals to improve lung health and advance diagnosis, treatment and care.

Founded in 2000, ELF works in partnership with the European Respiratory Society (ERS) to develop the union between lung health professionals and patients. Based in Sheffield (UK) and Brussels (Belgium) ELF has grown and developed a core team of specialists and a network of individual patients and patient organisations. Our ethos is openness, inclusiveness and collaboration. We believe in working together to improve lung health.

UK Address

442 Glossop Road Sheffield S10 2PX UK

Website

www.europeanlung.org

EU Address

51 Rue de Treves Brussels 1040 BE

Email

info@europeanlung.org

Charity number: 1118930







